Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository Shares (ADSs) from Nasdaq on October 28, 2025.
The company stated that Christopher Hill, current CFO of Adaptimmune, has been appointed CEO and a director, succeeding Andrew Rawcliffe. Mr. Rawcliffe and William Bertrand, formerly COO, have left Adaptimmune in connection with Adaptimmune’s restructuring.
Board member, Lawreance Alleva, has been appointed company chairman, succeeding David Mott. Other board members have resigned including Andrew Allen, Ali Behbahani, John Furey, Priti Hegde, and Kristen Hege.
The company has also initiated a process for deregistration of ADSs, which is expected to become effective on or about January 26, 2025.
